Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) Gross Margin: 2011-2025

Historic Gross Margin for Catalyst Pharmaceuticals (CPRX) over the last 7 years, with Sep 2025 value amounting to 84.73%.

  • Catalyst Pharmaceuticals' Gross Margin fell 29.00% to 84.73% in Q3 2025 from the same period last year, while for Sep 2025 it was 85.68%, marking a year-over-year decrease of 64.00%. This contributed to the annual value of 86.00% for FY2024, which is 95.00% down from last year.
  • Catalyst Pharmaceuticals' Gross Margin amounted to 84.73% in Q3 2025, which was down 1.40% from 85.94% recorded in Q2 2025.
  • Catalyst Pharmaceuticals' 5-year Gross Margin high stood at 88.35% for Q1 2023, and its period low was 80.82% during Q4 2021.
  • For the 3-year period, Catalyst Pharmaceuticals' Gross Margin averaged around 86.42%, with its median value being 86.20% (2023).
  • In the last 5 years, Catalyst Pharmaceuticals' Gross Margin plummeted by 348bps in 2021 and then skyrocketed by 413bps in 2023.
  • Over the past 5 years, Catalyst Pharmaceuticals' Gross Margin (Quarterly) stood at 80.82% in 2021, then soared by 76bps to 81.57% in 2022, then surged by 413bps to 85.70% in 2023, then plummeted by 96bps to 84.74% in 2024, then fell by 29bps to 84.73% in 2025.
  • Its Gross Margin was 84.73% in Q3 2025, compared to 85.94% in Q2 2025 and 87.33% in Q1 2025.